SM-1652 is primarily utilized in the field of pharmaceutical research and development, particularly in the study of cancer therapeutics. It has shown potential as an inhibitor of specific enzymes or proteins involved in tumor growth and proliferation, making it a candidate for targeted cancer therapy. Researchers are exploring its efficacy in preclinical studies to understand its mechanism of action and its ability to selectively target cancer cells while minimizing damage to healthy tissues. Additionally, SM-1652 is being investigated for its potential to enhance the effectiveness of existing treatments, such as chemotherapy or radiation, by sensitizing cancer cells to these therapies. Its application extends to the development of novel drug formulations and combination therapies aimed at improving patient outcomes in oncology.